1-methyl-pyrrole-2,5-dicarboxylic acid monomethyl ester | 67858-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-methyl-pyrrole-2,5-dicarboxylic acid monomethyl ester
• 英文别名: 5-(methoxycarbonyl)-1-methyl-1H-pyrrole-2-carboxylic acid；5-methoxycarbonyl-1-methylpyrrole-2-carboxylic acid
• CAS: 67858-50-8
• 化学式: C₈H₉NO₄
• 分子量: 183.164
• InChiKey: NHERZEGAVIIVOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methyl-pyrrole-2,5-dicarboxylic acid monomethyl ester 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 Methyl 5-carbonochloridoyl-1-methylpyrrole-2-carboxylate
  参考文献：
  名称：

  NEUROPROTECTIVE COMPOUNDS FOR THERAPEUTIC USE

  摘要：

  Provided are compounds that can reduce CD45+ CD4+ IFNy+ cells and inhibit or reduce inflammation. Also provided are methods of treating diseases characterized by inflammation using the compounds.

  公开号：

  WO2024155555A1
• 作为产物：
  描述：

  2-吡咯甲酸甲酯 在 三乙烯二胺 、 potassium permanganate 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 106.0h， 生成 1-methyl-pyrrole-2,5-dicarboxylic acid monomethyl ester
  参考文献：
  名称：

  NEUROPROTECTIVE COMPOUNDS FOR THERAPEUTIC USE

  摘要：

  Provided are compounds that can reduce CD45+ CD4+ IFNy+ cells and inhibit or reduce inflammation. Also provided are methods of treating diseases characterized by inflammation using the compounds.

  公开号：

  WO2024155555A1

文献信息

• ARYL HYDROCARBON RECEPTOR MODULATOR
  申请人：Ariagen, Inc.

  公开号：US20190307731A1

  公开（公告）日：2019-10-10

  Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R′ is H, CN, CH 2 (OH)R 0 , C m H 2m+1 , C n H 2n-1 , C n H 2n-3 , two R a are independently H or two R a together form ═O or ═N—W 3 —R 1 ; A is a C 6 to C 10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C 2 -C 10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, O, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C═N and interrupted by 1 to 3 heteroatoms selected from N, O, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C 6 to C 10 aromatic ring or a C 2 to C 10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, O, and S; and R is R c which is C-attached or R N which is N-attached. The compounds of formula (I) of the present invention can regulate AhR activity, and can be used to inhibit the growth of cancer cells and inhibit the metastasis and invasion of tumor cells.

  本发明揭示了一种化学式（I）的芳香烃受体调节剂及其药用可接受盐，其中R′为H、CN、CH2（OH）R0、CmH2m+1、CnH2n-1、CnH2n-3，两个Ra独立地为H或两个Ra共同形成═O或═N—W3—R1；A为未取代或取代1至3个R的C6至C10芳香环，或由N、O和S中选择的1至5个杂原子中断的C2-C10杂芳环，或含有C═N并由N、O和S中选择的1至3个杂原子中断的4至7个成员的非芳杂环，其中一个未取代或取代1至3个R；Q为R，或者是未取代或取代1至3个R并由N、O和S中断的C6至C10芳香环或C2至C10杂芳环；R为C-连接的Rc或N-连接的RN。本发明的化合物可以调节AhR活性，可用于抑制癌细胞的生长，以及抑制肿瘤细胞的转移和侵袭。
• [EN] BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER<br/>[FR] DÉRIVÉS BENZOXAZEPIN-4-(5H)-YLE ET LEUR UTILISATION POUR TRAITER LE CANCER
  申请人：EXELIXIS INC

  公开号：WO2010118208A1

  公开（公告）日：2010-10-14

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  这项发明涉及公式I的化合物及其药用可接受的盐或溶剂合物，以及制备和使用这些化合物的方法。
• Inhibitors of mTOR and Methods of Making and Using
  申请人：Anand Neel Kumar

  公开号：US20100305093A1

  公开（公告）日：2010-12-02

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。
• BARKER P.; GENDLER P.; RAPOPORT H., J. ORG. CHEM., 1978, 43 NO 25, 4849-4853
  作者：BARKER P.、 GENDLER P.、 RAPOPORT H.

  DOI：——

  日期：——
• ARYL HYDROCARBON RECEPTOR MODULATORS
  申请人：SHENZHEN IMMUNOVA PHARMACEUTICAL CO., LTD.

  公开号：US20190330201A1

  公开（公告）日：2019-10-31

  The disclosure discloses an aryl hydrocarbon receptor modulators of formula (I), and pharmaceutically acceptable salts, R′ is H, CN, CH 2 (OH)R 0 , C m H 2m+1 , C n H 2n-1 , C n H 2n-3 , two R a is independently H, or two R a together form ═O or ═N—W 3 —R 1 ; A is a C 6 to C 10 aromatic ring, or a C 2 to C 10 heteroaromatic ring containing 1 to 5 heteroatom from N, O and S, or 4 to 7 membered non-aromatic heterocyclic ring containing 1 to 3 heteroatom from N, O and S and C═N, which are with no substituent or substituted by 1 or 3 R; Q is R, or a C 6 to C 10 aromatic ring or a C 2 to C 10 heteroaromatic ring containing 1 to 5 heteroatom selected from N, O and S, which are with no substituent or substituted by 1 or 3 R; R is R c connected with C or R N connected with N.